<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><journal-title>PLoS Neglected Tropical Diseases</journal-title><issn pub-type="ppub">1935-2727</issn><issn pub-type="epub">1935-2735</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19221604</article-id><article-id pub-id-type="pmc">2640099</article-id><article-id pub-id-type="publisher-id">08-PNTD-RA-0232R2</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0000383</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cardiovascular Disorders</subject><subject>Infectious Diseases/Tropical and Travel-Associated Diseases</subject></subj-group></article-categories><title-group><article-title>Cardiac Alterations in Human African Trypanosomiasis (<italic>T.b. gambiense</italic>) with Respect to the Disease Stage and Antiparasitic Treatment</article-title><alt-title alt-title-type="running-head">Cardiac Alterations in Sleeping Sickness</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Blum</surname><given-names>Johannes A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schmid</surname><given-names>Caecilia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Burri</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hatz</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Olson</surname><given-names>Carol</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fungula</surname><given-names>Blaise</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kazumba</surname><given-names>Leon</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mangoni</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mbo</surname><given-names>Florent</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Deo</surname><given-names>Kambau</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mpanya</surname><given-names>Alain</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dala</surname><given-names>Amadeo</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Franco</surname><given-names>Jose R.</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref><xref ref-type="author-notes" rid="fn1"><sup>&#x000a4;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pohlig</surname><given-names>Gabriele</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zellweger</surname><given-names>Michael J.</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Swiss Tropical Institute, Basel, Switzerland</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Immtech Pharmaceuticals Inc., Vernon Hills, Illinois, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>H&#x000f4;pital Evang&#x000e9;lique de Vanga, Vanga, Democratic Republic of Congo</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Centre Neuro Psycho Pathologique, Kinshasa, Democratic Republic of Congo</addr-line></aff><aff id="aff5"><label>5</label><addr-line>H&#x000f4;pital General de Reference Bandundu, Bandundu, Democratic Republic of Congo</addr-line></aff><aff id="aff6"><label>6</label><addr-line>H&#x000f4;pital Evang&#x000e9;lique de Kikongo, Kikongo, Democratic Republic of Congo</addr-line></aff><aff id="aff7"><label>7</label><addr-line>CDTC Maluku, Maluku, Democratic Republic of Congo</addr-line></aff><aff id="aff8"><label>8</label><addr-line>Instituto de Combate e de Controlo das Tripanossom&#x000ed;ases, Luanda, Angola</addr-line></aff><aff id="aff9"><label>9</label><addr-line>Malteser International, Malteser Hospital, Yei, Southern Sudan</addr-line></aff><aff id="aff10"><label>10</label><addr-line>Cardiology Department, University Hospital, Basel, Switzerland</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Boelaert</surname><given-names>Marleen</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Institute of Tropical Medicine, Belgium</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>johannes.blum@unibas.ch</email></corresp><fn id="fn1" fn-type="current-aff"><label>&#x000a4;</label><p>Current address: Control of Neglected Tropical Diseases, Innovative and Intensified Disease Management, World Health Organization, Geneva, Switzerland</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: JAB CB CH CO GP MJZ. Performed the experiments: JAB BF LK PM FM DK AM AD JRF GP. Analyzed the data: JAB CS CB CO MJZ. Wrote the paper: JAB CB CH MJZ. Critically reviewed the paper: CH CO. Patient recruitment and examinations: BF LK PM FM DK AM AD JRF.</p></fn></author-notes><pub-date pub-type="collection"><month>2</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>17</day><month>2</month><year>2009</year></pub-date><volume>3</volume><issue>2</issue><elocation-id>e383</elocation-id><history><date date-type="received"><day>30</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2009</year></date></history><copyright-statement>Blum et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>In Human African Trypanosomiasis, neurological symptoms dominate and cardiac involvement has been suggested. Because of increasing resistance to the available drugs for HAT, new compounds are desperately needed. Evaluation of cardiotoxicity is one parameter of drug safety, but without knowledge of the baseline heart involvement in HAT, cardiologic findings and drug-induced alterations will be difficult to interpret. The aims of the study were to assess the frequency and characteristics of electrocardiographic findings in the first stage of HAT, to compare these findings to those of second stage patients and healthy controls and to assess any potential effects of different therapeutic antiparasitic compounds with respect to ECG changes after treatment.</p></sec><sec sec-type="methods"><title>Methods</title><p>Four hundred and six patients with first stage HAT were recruited in the Democratic Republic of Congo, Angola and Sudan between 2002 and 2007 in a series of clinical trials comparing the efficacy and safety of the experimental treatment DB289 to the standard first stage treatment, pentamidine. These ECGs were compared to the ECGs of healthy volunteers (n&#x0200a;&#x0003d;&#x0200a;61) and to those of second stage HAT patients (n&#x0200a;&#x0003d;&#x0200a;56).</p></sec><sec><title>Results</title><p>In first and second stage HAT, a prolonged QTc interval, repolarization changes and low voltage were significantly more frequent than in healthy controls. Treatment in first stage was associated with repolarization changes in both the DB289 and the pentamidine group to a similar extent. The QTc interval did not change during treatment.</p></sec><sec><title>Conclusions</title><p>Cardiac involvement in HAT, as demonstrated by ECG alterations, appears early in the evolution of the disease. The prolongation of the QTC interval comprises a risk of fatal arrhythmias if new drugs with an additional potential of QTC prolongation will be used. During treatment ECG abnormalities such as repolarization changes consistent with peri-myocarditis occur frequently and appear to be associated with the disease stage, but not with a specific drug.</p></sec></abstract><abstract abstract-type="summary"><title>Author Summary</title><p>In Human African Trypanosomiasis (HAT), neurological symptoms dominate and cardiac involvement has been suggested. Because of increasing resistance to the available drugs for HAT, new compounds are desperately needed. Evaluation of cardiotoxicity is one parameter of drug safety, but without knowledge of the baseline heart involvement in HAT, cardiologic findings and drug-induced alterations will be difficult to interpret. The electrocardiogram (ECG) is a tool to evaluate cardiac involvement and the risk of arrythmias. We analysed the ECG of 465 HAT patients and compared them with the ECG of 61 healthy volunteers. In HAT patients the QTc interval was prolonged. This comprises a risk of fatal arrhythmias if new drugs with antiarrhythmic potential will be used. Further, repolarization changes and low voltage were more frequent than in healthy controls. This could be explained by an inflammation of the heart. Treatment of HAT was associated with appearance of repolarization changes but not with a QTc prolongation. These changes appear to be associated with the disease, but not with a specific drug. The main conclusion of this study is that heart involvement is frequent in HAT and mostly well tolerated. However, it can become relevant, if new compounds with antiarrhythmic potential will be used.</p></abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Human African Trypanosomiasis (HAT) or sleeping sickness evolves in two stages, the first or early (hemo-lymphatic) stage and the second or late (meningo-encephalitic) stage which is characterized by invasion of the central nervous system (CNS) by trypanosomes. Neuropsychiatric disturbances are the most prominent and best documented features of the disease <xref ref-type="bibr" rid="pntd.0000383-Blum1">&#x0005b;1&#x0005d;</xref>. Cardiac involvement plays an important role in American trypanosomiasis (Chagas' disease); however, in the African form, cardiac involvement has been suggested but has never been studied systematically in the first stage of the disease. Cardiac involvement has been observed in up to 73&#x00025; of HAT patients in post mortem histological studies <xref ref-type="bibr" rid="pntd.0000383-Adams1">&#x0005b;2&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Collomb1">&#x0005b;3&#x0005d;</xref>. Those findings are supported by the recent study of Blum <italic>et al</italic> <xref ref-type="bibr" rid="pntd.0000383-Blum2">&#x0005b;4&#x0005d;</xref> that showed cardiac alterations in 71&#x00025; of second stage HAT patients, but are in contrast to previous studies, where ECG findings were reported in only 35&#x02013;48&#x00025; of the patients <xref ref-type="bibr" rid="pntd.0000383-Fouchet1">&#x0005b;5&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pntd.0000383-Tsala1">&#x0005b;7&#x0005d;</xref>. The latter studies included both first and second-stage HAT patients. A low prevalence of ECG findings in first stage disease could explain this discrepancy. Thus, cardiac involvement, as documented by ECG findings, may parallel CNS involvement and ECG findings could be used as additional tool for assessing the advancement of the disease.</p><p>Because of increasing resistance to the available drugs for HAT, new compounds or drug combinations are desperately needed. Evaluation of cardiotoxicity and the risk of cardiac arrhythmia is one parameter of drug safety, but without knowledge of heart involvement in HAT, cardiologic findings and drug-induced ECG alterations will be difficult to interpret.</p><p>Pentamidine administered intramuscularly is currently the primary treatment for first stage HAT. A large number of diamidine compounds have been synthesized in an attempt to develop an oral agent for this disease. DB289 (pafuramidine maleate) is one of these diamidine compounds. It can be orally administered and showed good efficacy against first stage HAT in Phase II trials. Since diamidines such as pentamidine have been shown to have arrhythmic potential <xref ref-type="bibr" rid="pntd.0000383-Kuryshev1">&#x0005b;8&#x0005d;</xref>, knowledge of HAT cardiopathy and scrupulous analysis of the potential cardiac effects of new antiparasitic drugs is essential.</p><p>The overall aim of the study was to assess the cardiac involvement in first stage HAT by ECG examination and to study the effect of different antiparasitic drugs on ECG findings.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Objectives</title><p>The objectives of this study were to assess the frequency and character of ECG findings in patients with first stage HAT and to compare them to healthy control subjects and to second stage HAT patients. Secondary objectives were to assess differences between administered HAT therapies, including ECG changes during and after treatment, and to discuss the findings with respect to clinical relevance and tolerability of medical therapy.</p></sec><sec id="s2b"><title>Criteria of selection of trials</title><p>The objectives were to study and characterize ECG alterations in T.<italic>b. gambiense</italic> patients with respect to the stage of the disease (first versus second stage) and treatment induced alterations (baseline versus after treatment).</p><p>Only studies with clear definition of ECG criteria and complete ECG description (including QTc intervals), description of the stage of the disease and ECG before and after treatment were included. Using these criteria the following studies were not included:</p><list list-type="bullet"><list-item><p>Studies on ECG alterations of patients infected with <italic>T.b. rhodesiense</italic> <xref ref-type="bibr" rid="pntd.0000383-Jones1">&#x0005b;9&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pntd.0000383-Koten1">&#x0005b;11&#x0005d;</xref></p></list-item><list-item><p>Studies without indication, in which stage the patient was <xref ref-type="bibr" rid="pntd.0000383-Fouchet1">&#x0005b;5&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pntd.0000383-Tsala1">&#x0005b;7&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Bertrand2">&#x0005b;12&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Bertrand3">&#x0005b;13&#x0005d;</xref></p></list-item><list-item><p>Studies without ECG at baseline and after treatment alterations <xref ref-type="bibr" rid="pntd.0000383-Collomb1">&#x0005b;3&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Bertrand1">&#x0005b;6&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Tsala1">&#x0005b;7&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Bertrand2">&#x0005b;12&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Bertrand3">&#x0005b;13&#x0005d;</xref></p></list-item><list-item><p>Studies without clear inclusion/exclusion criteria or definition of ECG</p><list list-type="bullet"><list-item><p>Unclear, why only 28/100 patients had an ECG <xref ref-type="bibr" rid="pntd.0000383-Collomb1">&#x0005b;3&#x0005d;</xref></p></list-item><list-item><p>ECG description vague and no indication of QTc <xref ref-type="bibr" rid="pntd.0000383-Fouchet1">&#x0005b;5&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pntd.0000383-Tsala1">&#x0005b;7&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Bertrand3">&#x0005b;13&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Bertrand4">&#x0005b;14&#x0005d;</xref></p></list-item></list></list-item></list></sec><sec id="s2c"><title>Participants</title><p>Electrocardiograms (ECG) were performed prior to and following treatment and analyzed in a total of 523 participants; 406 were patients with first stage HAT, 56 with second stage HAT and 61 were healthy controls. Patients and controls from different clinical trials are included in the present analysis.</p><sec id="s2c1"><title>First stage patients</title><p>First stage HAT patients were recruited in the frame of phase II &#x00026; III trials (International Standard Randomised Controlled Trial Number Register: ISRCTN85534673, 289-C-003 NCT 00802594, 289-C-006 NCT 00803933) conducted for the development of DB289 (pafuramidine maleate) in the Democratic Republic of Congo (Maluku, Vanga, Kikongo, Bandundu), Angola (U&#x000ed;ge) and Sudan (Yei). Between April 2002 and March 2007 a total of 415 patients older than 12 years were enrolled in these trials and 406 of them had sufficient ECG and treatment data to be included in this analysis. 177 patients received pentamidine (4 mg/kg daily) for 7 consecutive days by intramuscular injection. 64 patients received oral DB289 (200 mg total daily dose, divided twice daily) for 5 days and 165 patients had oral DB289 (200 mg total daily dose, divided twice daily) for 10 days.</p></sec><sec id="s2c2"><title>Second stage patients and healthy controls</title><p>59 consecutive patients older than 15 years with parasitologically confirmed second stage HAT were enrolled in a separate prospective cohort study <xref ref-type="bibr" rid="pntd.0000383-Blum2">&#x0005b;4&#x0005d;</xref>. Three patients died either before or during treatment and were excluded from the current analysis. The control group consisted of 61 healthy persons with no previous history of HAT, matched for gender and age (&#x0002b;/&#x02212;5 years). Data were collected between July 2004 and September 2005 in the DRC at the University Clinic in Kinshasa (Centre Neuro Psycho Pathologique), and at the H&#x000f4;pital Evang&#x000e9;lique de Vanga, Bandundu. Melarsoprol was the treatment of first line in patients with stage II HAT, 18 patients got melarsoprol intravenously (2.2 mg/kg/day) for 10 consecutive days <xref ref-type="bibr" rid="pntd.0000383-Burri1">&#x0005b;15&#x0005d;</xref> and 29 patients received the standard melarsoprol treatment <xref ref-type="bibr" rid="pntd.0000383-Blum3">&#x0005b;16&#x0005d;</xref> of increasing doses in 3 series of 3 days with rest periods of 7 days between the series. Eflornithine was reserved for patients with clinically advanced disease or after treatment failure with melarsoprol; 9 patients received eflornithine (400 mg/kg/day) via intravenous infusion over 14 days <xref ref-type="bibr" rid="pntd.0000383-Chappuis1">&#x0005b;17&#x0005d;</xref>.</p></sec></sec><sec id="s2d"><title>Procedures</title><p>All HAT patients and healthy controls underwent a clinical assessment, including medical history, baseline physical examination, blood sampling for hematology and chemistry, and ECG. To estimate the normal intra-individual fluctuation of ECG parameters, two ECG recordings per subject were obtained at baseline. ECG changes appearing after treatment were compared to these intra-individual ECG changes. ECG data were also obtained during treatment in first stage HAT patients in all patients treated with DB 289 and in 40 patients treated with pentamidine. A clinical assessment was performed and the ECG was repeated after completion of treatment of HAT.</p><p>All ECG tracings were interpreted by a single reader using standardized criteria as described below. The ECG data for the first stage HAT patients were compared to the ECG data from the healthy controls and the second stage HAT patients.</p></sec><sec id="s2e"><title>ECG interpretation</title><p>The PQ, QRS and QT intervals were measured manually by the principal investigator in three consecutive cycles and mean values were calculated. Measures of the intervals were performed in lead II, when feasible with lead V2 or I as second choice. QTc was calculated by the Bazett formula (QTc&#x0200a;&#x0003d;&#x0200a;QT/SQR (RR). QTc shorter than 440 ms and shorter than 460 ms were considered normal for men and women, respectively <xref ref-type="bibr" rid="pntd.0000383-AlKhatib1">&#x0005b;18&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Moss1">&#x0005b;19&#x0005d;</xref> and because a QTc longer than 500 ms is known as predictor of torsades de pointes <xref ref-type="bibr" rid="pntd.0000383-Moss1">&#x0005b;19&#x0005d;</xref> both limits were used for the analysis. For overall ECG interpretation, the following criteria were used. Right atrial hypertrophy (RAH): p&#x0003e;2.5 mV; left atrial hypertrophy (LAH): p&#x0003e;120 ms; right ventricular hypertrophy (RVH): Sokolow index right: RV1 and S V5&#x0003e;1.05 mV, left ventricular hypertrophy (LVH): Cornell voltage: R aVL and SV3 men &#x0003e;2.8; women &#x0003e;2.0; peripheral low voltage: R I and RII and R III&#x0003c;1.6 mV; PR depression: &#x0003e;0.8 mV; ST elevation: &#x0003e;0.1 mV without notch, concave, from deep S; ST depression: &#x0003e;1 mV; repolarization changes: limb leads: discordant in at least one lead; precordial leads: negative in either V3, V4, V5 or V6. Early repolarization type: ST elevation concave, notch at the J point, positive T waves. Normal ECG included axis deviation, early repolarization type <xref ref-type="bibr" rid="pntd.0000383-Wang1">&#x0005b;20&#x0005d;</xref>, ST elevation &#x0003e;0.1 mV without notch, concave, from deep S in precordial leads <xref ref-type="bibr" rid="pntd.0000383-Wang1">&#x0005b;20&#x0005d;</xref> and partial right bundle brunch block (RBBB). Minor ECG changes included intraventricular conduction delay, left or right atrial hypertrophy, isolated premature atrial or ventricular captures and left anterior hemiblock (LAHB). Major changes included: AV block I&#x02013;III, low voltage, left and right ventricular hypertrophy, complete bundle branch block, PR depression, ST depression and repolarization changes.</p></sec><sec id="s2f"><title>Ethical considerations</title><p>Written informed consent (illiterates signed by fingerprint) was obtained from all study participants. Ethical approval was granted by the Ethics Committees of the DRC, Angola, South Sudan and the Ethics Committee for the two cantons of Basel, Switzerland (Ethikkomission beider Basel).</p></sec><sec id="s2g"><title>Data analysis</title><p>Data from the various studies were pooled into one single database that contained the clinical examination, demographic data and the ECG details. Analysis was done using the statistical software package STATA 9.0 (<ext-link ext-link-type="uri" xlink:href="http://www.stata.com">www.stata.com</ext-link>). All continuous variables are reported as mean&#x000b1;SD. A p-value&#x0003c;0.05 was considered statistically significant. Nominal variables were compared using the <italic>&#x003a7;</italic><sup>2</sup>- test. Comparisons between the patient groups and treatments were performed using the t-test, ANOVA plus Bonferroni correction , the Kruskal Wallis or Mann Whitney U tests where appropriate.</p></sec></sec><sec id="s3"><title>Results</title><p>Patient baseline characteristics are summarized in <xref ref-type="table" rid="pntd-0000383-t001">Table 1</xref>. Age and gender distribution were similar among the disease stages, the HAT treatment groups and the healthy controls, respectively. Pyrimethamine-sulfadoxine (SP) was given as first line malaria treatment prior to HAT treatment in all centers with the exception of CNPP Kinshasa, where quinine was used as standard malaria treatment due to the high level of SP resistance in Kinshasa.</p><table-wrap id="pntd-0000383-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000383.t001</object-id><label>Table 1</label><caption><title>Demographics and baseline description of the HAT patients and controls.</title></caption><graphic id="pntd-0000383-t001-1" xlink:href="pntd.0000383.t001"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000383-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Healthy controls</td><td colspan="4" align="left" rowspan="1">HAT stage 1</td><td colspan="4" align="left" rowspan="1">HAT stage 2</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1"/><td colspan="2" align="left" rowspan="1">DB289</td><td colspan="2" align="left" rowspan="1">pentamidine</td><td colspan="2" align="left" rowspan="1">melarsoprol</td><td colspan="2" align="left" rowspan="1">eflornithine</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td></tr></thead><tbody><tr><td colspan="11" align="left" rowspan="1"><bold>Demographics</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Number of patients (Total N&#x0200a;&#x0003d;&#x0200a;526)</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">229</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">177</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age, mean (SD)</td><td align="left" rowspan="1" colspan="1">35 (13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">33 (13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">33 (14)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">34 (12)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">36 (11)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gender (male/female)</td><td align="left" rowspan="1" colspan="1">33/28</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">80/149</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">67/110</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">23/24</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">4/5</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td colspan="11" align="left" rowspan="1"><bold>Diagnostics</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Malaria postive<xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">na</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">9.6</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">10.2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">4.3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Filaria positive<xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">na</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">8.7</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">10.2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulse, mean (SD)</td><td align="left" rowspan="1" colspan="1">72 (11)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">76 (14)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">75 (13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">75 (14)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">79 (16)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pulse&#x0003e;100</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">4.4</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood pressure, mean systolic (SD)</td><td align="left" rowspan="1" colspan="1">111 (13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">107 (13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">108 (15)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">105 (14)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">109 (24)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="11" align="left" rowspan="1"><bold>Malaria pre-treatment</bold><xref ref-type="table-fn" rid="nt103">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Pyrimethamine/Sulfadoxine</td><td align="left" rowspan="1" colspan="1">na</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">203</td><td align="left" rowspan="1" colspan="1">88.6</td><td align="left" rowspan="1" colspan="1">154</td><td align="left" rowspan="1" colspan="1">87.0</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">61.7</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Amodiaquine</td><td align="left" rowspan="1" colspan="1">na</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3.4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Chloroquin</td><td align="left" rowspan="1" colspan="1">na</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Quinine</td><td align="left" rowspan="1" colspan="1">na</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">3.9</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">38.3</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">100.0</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>na: not applicable, tests not done or data not available</p></fn><fn id="nt102"><label>a</label><p>malaria and filaria testing are not standard and were only systematically applied in the DB289 trial series</p></fn><fn id="nt103"><label>b</label><p>other anti-parasitic treatment was administered during the 3 days prior to initiation of HAT treatment</p></fn></table-wrap-foot></table-wrap><p>The ECG baseline intervals and characteristics are listed by disease stage in <xref ref-type="table" rid="pntd-0000383-t002">Table 2</xref>. At baseline, QTc prolongation, which was defined as &#x0003e;440 ms in men and, &#x0003e;460 ms in women, was observed in 11&#x02013;13&#x00025; of all HAT patients. These QTc values are considered to represent an increased risk for arrhythmia. Only one patient had a QTc interval over 500 ms, which is associated with an elevated risk for torsade de pointes. The proportion of major ECG findings indicating heart involvement was significantly lower (p-value&#x0200a;&#x0003d;&#x0200a;0.0001) in first stage (53.5&#x00025;) than in second stage HAT (69.5&#x00025;). The QTc interval of HAT patients treated with melarsoprol following malaria treatment was 412 msec in the sulfadoxin/pyrimethamin group (SD 19) and 431 msec (SD 24) in the quinine group.</p><table-wrap id="pntd-0000383-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000383.t002</object-id><label>Table 2</label><caption><title>ECG findings at baseline, by disease stage compared to healthy subjects.</title></caption><graphic id="pntd-0000383-t002-2" xlink:href="pntd.0000383.t002"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000383-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Healthy controls</td><td align="left" rowspan="1" colspan="1">HAT stage 1</td><td align="left" rowspan="1" colspan="1">HAT stage 2</td><td align="left" rowspan="1" colspan="1">p-value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">N&#x0200a;&#x0003d;&#x0200a;61</td><td align="left" rowspan="1" colspan="1">N&#x0200a;&#x0003d;&#x0200a;406</td><td align="left" rowspan="1" colspan="1">N&#x0200a;&#x0003d;&#x0200a;56</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td colspan="5" align="left" rowspan="1"><bold>ECG Intervals (msec; mean (SD))</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">PQ</td><td align="left" rowspan="1" colspan="1">163 (16)</td><td align="left" rowspan="1" colspan="1">159 (24)</td><td align="left" rowspan="1" colspan="1">169 (25)</td><td align="left" rowspan="1" colspan="1">0.008<xref ref-type="table-fn" rid="nt107">&#x003b3;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">QRS</td><td align="left" rowspan="1" colspan="1">82 (11)</td><td align="left" rowspan="1" colspan="1">80 (9)</td><td align="left" rowspan="1" colspan="1">82 (8)</td><td align="left" rowspan="1" colspan="1">0.076</td></tr><tr><td align="left" rowspan="1" colspan="1">QTc</td><td align="left" rowspan="1" colspan="1">403 (21)</td><td align="left" rowspan="1" colspan="1">421 (28)</td><td align="left" rowspan="1" colspan="1">423 (25)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt105">&#x003b1;</xref><xref ref-type="table-fn" rid="nt106">&#x003b2;</xref></td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>ECG Findings (&#x00025;)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">atrial fibrillation/flutter</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.862</td></tr><tr><td align="left" rowspan="1" colspan="1">premature atrial capture</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.450</td></tr><tr><td align="left" rowspan="1" colspan="1">premature ventricular capture</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">3.6</td><td align="left" rowspan="1" colspan="1">0.285</td></tr><tr><td align="left" rowspan="1" colspan="1">bigeminus</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.871</td></tr><tr><td align="left" rowspan="1" colspan="1">AV block 1</td><td align="left" rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">3.7</td><td align="left" rowspan="1" colspan="1">7.1</td><td align="left" rowspan="1" colspan="1">0.449</td></tr><tr><td align="left" rowspan="1" colspan="1">AV block 2</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">RAH (Right atrial hypertrophy)</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">0.334</td></tr><tr><td align="left" rowspan="1" colspan="1">LAH (Left atrial hypertrophy)</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">5.4</td><td align="left" rowspan="1" colspan="1">0.394</td></tr><tr><td align="left" rowspan="1" colspan="1">RVH (Right ventricular hypertrophy)</td><td align="left" rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">5.2</td><td align="left" rowspan="1" colspan="1">3.6</td><td align="left" rowspan="1" colspan="1">0.732</td></tr><tr><td align="left" rowspan="1" colspan="1">LVH (Left ventricular hypertrophy)</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">0.977</td></tr><tr><td align="left" rowspan="1" colspan="1">pathologic Q</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.551</td></tr><tr><td align="left" rowspan="1" colspan="1">RBBB (Right bundle brunch block)</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.581</td></tr><tr><td align="left" rowspan="1" colspan="1">LBBB (Left bundle brunch block)</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">LAHB (Left anterior hemiblock)</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.584</td></tr><tr><td align="left" rowspan="1" colspan="1">RBBB and LAHB</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">0.469</td></tr><tr><td align="left" rowspan="1" colspan="1">repolarisation changes</td><td align="left" rowspan="1" colspan="1">6.6</td><td align="left" rowspan="1" colspan="1">35.2</td><td align="left" rowspan="1" colspan="1">32.1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt105">&#x003b1;</xref><xref ref-type="table-fn" rid="nt106">&#x003b2;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">low voltage</td><td align="left" rowspan="1" colspan="1">6.7</td><td align="left" rowspan="1" colspan="1">20.0</td><td align="left" rowspan="1" colspan="1">30.4</td><td align="left" rowspan="1" colspan="1">0.005<xref ref-type="table-fn" rid="nt105">&#x003b1;</xref><xref ref-type="table-fn" rid="nt106">&#x003b2;</xref><xref ref-type="table-fn" rid="nt107">&#x003b3;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">QTc prolongation<xref ref-type="table-fn" rid="nt104">a</xref></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">11.1</td><td align="left" rowspan="1" colspan="1">12.5</td><td align="left" rowspan="1" colspan="1">0.021<xref ref-type="table-fn" rid="nt105">&#x003b1;</xref><xref ref-type="table-fn" rid="nt106">&#x003b2;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">minor changes</td><td align="left" rowspan="1" colspan="1">16.4</td><td align="left" rowspan="1" colspan="1">9.6</td><td align="left" rowspan="1" colspan="1">7.1</td><td align="left" rowspan="1" colspan="1">0.193</td></tr><tr><td align="left" rowspan="1" colspan="1">major changes</td><td align="left" rowspan="1" colspan="1">19.7</td><td align="left" rowspan="1" colspan="1">53.5</td><td align="left" rowspan="1" colspan="1">67.9</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt105">&#x003b1;</xref><xref ref-type="table-fn" rid="nt106">&#x003b2;</xref><xref ref-type="table-fn" rid="nt107">&#x003b3;</xref></td></tr></tbody></table><table-wrap-foot><fn id="nt104"><label>a</label><p>for male &#x0003e;440 msec, female &#x0003e;460 msec</p></fn><fn id="nt105"><label>&#x003b1;</label><p>for healthy control vs HATstage 1 p&#x0003c;0.05</p></fn><fn id="nt106"><label>&#x003b2;</label><p>for healthy control vs HATstage 2 p&#x0003c;0.05</p></fn><fn id="nt107"><label>&#x003b3;</label><p>for HAT stage 1 vs HATstage 2 p&#x0003c;0.05</p></fn></table-wrap-foot></table-wrap><p>Changes of ECG intervals and findings according to the different treatment groups are shown in the <xref ref-type="table" rid="pntd-0000383-t003">Table 3</xref> and <xref ref-type="table" rid="pntd-0000383-t004">4</xref>.</p><table-wrap id="pntd-0000383-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000383.t003</object-id><label>Table 3</label><caption><title>ECG interval changes over time, by treatment.</title></caption><graphic id="pntd-0000383-t003-3" xlink:href="pntd.0000383.t003"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000383-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">HAT Stage 1</td><td colspan="3" align="left" rowspan="1">HAT Stage 2</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DB289</td><td align="left" rowspan="1" colspan="1">pentamidine</td><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">melarsoprol</td><td align="left" rowspan="1" colspan="1">eflornithine</td><td align="left" rowspan="1" colspan="1">p-value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(N&#x0200a;&#x0003d;&#x0200a;229)</td><td align="left" rowspan="1" colspan="1">(N&#x0200a;&#x0003d;&#x0200a;177)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(N&#x0200a;&#x0003d;&#x0200a;47)</td><td align="left" rowspan="1" colspan="1">(N&#x0200a;&#x0003d;&#x0200a;9)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1"><bold>PQ msec, mean (SD)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">161 (26)</td><td align="left" rowspan="1" colspan="1">157 (20)</td><td align="left" rowspan="1" colspan="1">0.091</td><td align="left" rowspan="1" colspan="1">169 (26)</td><td align="left" rowspan="1" colspan="1">170 (20)</td><td align="left" rowspan="1" colspan="1">0.914</td></tr><tr><td align="left" rowspan="1" colspan="1">During treatment</td><td align="left" rowspan="1" colspan="1">163 (24)</td><td align="left" rowspan="1" colspan="1">155 (26)<xref ref-type="table-fn" rid="nt108">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">0.056</td><td align="left" rowspan="1" colspan="1">nd</td><td align="left" rowspan="1" colspan="1">nd</td><td align="left" rowspan="1" colspan="1">na</td></tr><tr><td align="left" rowspan="1" colspan="1">At end of treatment</td><td align="left" rowspan="1" colspan="1">166 (25)</td><td align="left" rowspan="1" colspan="1">161 (21)</td><td align="left" rowspan="1" colspan="1">0.037</td><td align="left" rowspan="1" colspan="1">168 (26)</td><td align="left" rowspan="1" colspan="1">158 (14)</td><td align="left" rowspan="1" colspan="1">0.269</td></tr><tr><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">0.810</td><td align="left" rowspan="1" colspan="1">0.683</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.557</td><td align="left" rowspan="1" colspan="1">0.714</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="7" align="left" rowspan="1"><bold>QRS msec, mean (SD)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">79 (8)</td><td align="left" rowspan="1" colspan="1">80 (9)</td><td align="left" rowspan="1" colspan="1">0.237</td><td align="left" rowspan="1" colspan="1">82 (8)</td><td align="left" rowspan="1" colspan="1">79 (11)</td><td align="left" rowspan="1" colspan="1">0.337</td></tr><tr><td align="left" rowspan="1" colspan="1">During treatment</td><td align="left" rowspan="1" colspan="1">79 (8)</td><td align="left" rowspan="1" colspan="1">82 (9)<xref ref-type="table-fn" rid="nt108">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">0.033</td><td align="left" rowspan="1" colspan="1">nd</td><td align="left" rowspan="1" colspan="1">nd</td><td align="left" rowspan="1" colspan="1">na</td></tr><tr><td align="left" rowspan="1" colspan="1">At end of treatment</td><td align="left" rowspan="1" colspan="1">79 (8)</td><td align="left" rowspan="1" colspan="1">81 (13)</td><td align="left" rowspan="1" colspan="1">0.057</td><td align="left" rowspan="1" colspan="1">79 (6)</td><td align="left" rowspan="1" colspan="1">77 (5)</td><td align="left" rowspan="1" colspan="1">0.353</td></tr><tr><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">0.699</td><td align="left" rowspan="1" colspan="1">0.939</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.483</td><td align="left" rowspan="1" colspan="1">0.155</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="7" align="left" rowspan="1"><bold>QTc msec, mean (SD)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">422 (26)</td><td align="left" rowspan="1" colspan="1">419 (30)</td><td align="left" rowspan="1" colspan="1">0.282</td><td align="left" rowspan="1" colspan="1">420 (23)</td><td align="left" rowspan="1" colspan="1">441 (29)</td><td align="left" rowspan="1" colspan="1">0.020</td></tr><tr><td align="left" rowspan="1" colspan="1">During treatment</td><td align="left" rowspan="1" colspan="1">419 (27)</td><td align="left" rowspan="1" colspan="1">413 (22)<xref ref-type="table-fn" rid="nt108">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">0.185</td><td align="left" rowspan="1" colspan="1">nd</td><td align="left" rowspan="1" colspan="1">nd</td><td align="left" rowspan="1" colspan="1">na</td></tr><tr><td align="left" rowspan="1" colspan="1">At end of treatment</td><td align="left" rowspan="1" colspan="1">419 (24)</td><td align="left" rowspan="1" colspan="1">417 (24)</td><td align="left" rowspan="1" colspan="1">0.406</td><td align="left" rowspan="1" colspan="1">427 (27)</td><td align="left" rowspan="1" colspan="1">408 (23)</td><td align="left" rowspan="1" colspan="1">0.053</td></tr><tr><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">0.355</td><td align="left" rowspan="1" colspan="1">0.417</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.183</td><td align="left" rowspan="1" colspan="1">0.021</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="nt108"><label>&#x0002a;</label><p>ECG during treatment was only performed in n&#x0200a;&#x0003d;&#x0200a;40 patients in the pentamidine group</p></fn><fn id="nt109"><p>nd: ECGs not done</p></fn><fn id="nt110"><p>na: not applicable</p></fn></table-wrap-foot></table-wrap><table-wrap id="pntd-0000383-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000383.t004</object-id><label>Table 4</label><caption><title>ECG changes during treatment (baseline vs end of treatment), by treatment.</title></caption><graphic id="pntd-0000383-t004-4" xlink:href="pntd.0000383.t004"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000383-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Intraindividual changes at baseline</td><td colspan="3" align="left" rowspan="1">HAT Stage 1</td><td colspan="2" align="left" rowspan="1">HAT Stage 2</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DB289</td><td align="left" rowspan="1" colspan="1">Pentamidine</td><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">Melarsoprol</td><td align="left" rowspan="1" colspan="1">DFMO</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(N&#x0200a;&#x0003d;&#x0200a;526)</td><td align="left" rowspan="1" colspan="1">(N&#x0200a;&#x0003d;&#x0200a;229)</td><td align="left" rowspan="1" colspan="1">(N&#x0200a;&#x0003d;&#x0200a;177)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(N&#x0200a;&#x0003d;&#x0200a;47)</td><td align="left" rowspan="1" colspan="1">(N&#x0200a;&#x0003d;&#x0200a;9)</td></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1"><bold>Repolarisation changes (&#x00025;)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">appearance/aggravation</td><td align="left" rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1">5.7</td><td align="left" rowspan="1" colspan="1">4.5</td><td align="left" rowspan="1" colspan="1">0.300</td><td align="left" rowspan="1" colspan="1">29.8</td><td align="left" rowspan="1" colspan="1">44.4</td></tr><tr><td align="left" rowspan="1" colspan="1">disappearance/improvement</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">13.1</td><td align="left" rowspan="1" colspan="1">9.6</td><td align="left" rowspan="1" colspan="1">0.138</td><td align="left" rowspan="1" colspan="1">12.8</td><td align="left" rowspan="1" colspan="1">11.1</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Low voltage (&#x00025;)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">appearance</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">0.363</td><td align="left" rowspan="1" colspan="1">6.4</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">disappearance</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">0.625</td><td align="left" rowspan="1" colspan="1">4.3</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>AV block I (&#x00025;)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">appearance</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">0.190</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">disappearance</td><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">0.872</td><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap><p>During treatment, no patient in the DB289 or the pentamidine groups developed a QTc longer than 500 ms. One patient with a QTc longer than 500 ms at baseline had a normal QTc after treatment. In the group of second stage patients, one patient developed a significantly prolonged QTc interval during melarsoprol treatment.</p><p>The development or disappearance of AV block I consisted mostly of increases or decreases of a few milliseconds, usually from just below to just above the upper limit of normal (200 ms) or vise versa. During the treatment period in the DB289 group no relevant conduction problems such as AV block II or III or ventricular arrhythmias were seen. In the pentamidine group, two patients developed an AV block II (Type Wenckebach), which resolved spontaneously and was asymptomatic. One patient with second stage HAT developed a bigeminal rhythm during treatment with melarsoprol, which subsided after administration of corticosteroids. There were no further significant changes in rhythm or conduction, such as ventricular arrhythmia, appearance of AV block III or formation of bundle branch block, observed in ECG recordings during treatment compared to baseline or during treatment compared to after treatment.</p></sec><sec id="s4"><title>Discussion</title><p>To our knowledge this is the first study comparing ECG data of first and second stage HAT patients and also healthy controls. This study comprises ECG recordings of 523 participants, the largest number of patients to date in a population with HAT.</p><p>The mean QTc interval was significantly longer in HAT patients compared to healthy controls and increased slightly with the progression of the disease from first to second stage. As HAT itself was associated with QTc prolongation in more than 10&#x00025; of patients, the additional risk of a drug with potential QTc prolongation properties has to be considered because of the risk of fatal arrhythmias. The mean QTc interval of the eflornithine group at baseline was longer than in the other groups. Eflornithine was given to patients with more advanced disease. In addition, these patients were treated with quinine before the baseline ECG was obtained, which has a known effect on QTc <xref ref-type="bibr" rid="pntd.0000383-White1">&#x0005b;21&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Luzzi1">&#x0005b;22&#x0005d;</xref>. Pretreatment with quinine in the melarsoprol group had an additional influence on QTc prolongation. Most patients in the other groups received SP for antimalarial treatment prior to obtaining baseline ECG recordings, and SP has a negligible effect on the QTc interval <xref ref-type="bibr" rid="pntd.0000383-Luzzi2">&#x0005b;23&#x0005d;</xref>.</p><p>Cardiac involvement, as defined by major ECG alterations, was found in more than half of the patients with first stage HAT and in about two thirds in the second stage. Thus, ECG alterations are not a suitable additional tool for stage determination. Repolarization changes (35&#x00025;), low voltage (20&#x00025;) and QTc prolongation (11&#x00025;) were the major abnormalities observed. Conduction delays, such as bundle branch block or AV block, and pathologic Q waves (signs of necrosis) were not found more often than in healthy controls. An explanation of the repolarization changes and the low voltage observed in the current study cannot be inferred from these data. However, observations from former histological studies showing a diffuse, interstitial lympho-mono-histiocytic infiltration and edema in the pericardium, myocardium, and endocardium without myocardial necrosis <xref ref-type="bibr" rid="pntd.0000383-Adams1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pntd.0000383-Collomb1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pntd.0000383-Bertrand5">&#x0005b;24&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pntd.0000383-Poltera3">&#x0005b;27&#x0005d;</xref>, support the hypothesis that repolarization changes and low voltage represent peri-myocarditis. The presence of pericardial involvement has been reported in a prior echocardiographic study, where pericarditis with pericardial effusion was demonstrated in 12&#x00025; of patients <xref ref-type="bibr" rid="pntd.0000383-Tsala1">&#x0005b;7&#x0005d;</xref>. In our study, repolarization changes were similar in both stages suggesting that peri-myocarditis appears early in the disease. The lower proportion of low voltage in first stage compared to second stage patients (20&#x00025; versus 30.5&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.004) suggests that pericardial effusion becomes more significant later in the disease.</p><p>None of the patients with first stage HAT were diagnosed with congestive heart failure. In second stage HAT, NT-proBNP values were significantly higher in patients than in controls <xref ref-type="bibr" rid="pntd.0000383-Blum2">&#x0005b;4&#x0005d;</xref>, and 23&#x00025; of these patients had values that have been associated with an ejection fraction of less than 40&#x00025; <xref ref-type="bibr" rid="pntd.0000383-CostelloBoerrigter1">&#x0005b;28&#x0005d;</xref>. However, the overall relatively low NT-proBNP levels indicate that most HAT patients probably did not have clinically relevant congestive heart failure. Thus, heart failure appears infrequently and/or late in the disease progression of HAT.</p><p>In the following sections the effect of antiparasitic treatment to ECG findings will be discussed. The mean PQ intervals and QTc time did not increase during treatment of first stage disease in either the DB289 or the pentamidine group. The appearance and disappearance of AV block I was in the range of the normal intra-individual fluctuation in all treatment groups. However, the appearance of AV block II and bigeminal rhythm showed the potential of relevant conduction problems under treatment. Clinical case reports of conduction delays in patients with HAT have been published. A German tourist with <italic>T.b. gambiense</italic> infection developed transient AV block III, supraventricular tachycardia and ventricular premature captures (class Lown IV b) <xref ref-type="bibr" rid="pntd.0000383-Damian1">&#x0005b;29&#x0005d;</xref> and a British soldier infected with <italic>T.b. rhodesiense</italic> developed transient second degree heart block <xref ref-type="bibr" rid="pntd.0000383-Croft1">&#x0005b;30&#x0005d;</xref>. Based on unpublished observations, there is a minority of patients who die suddenly without explanation and sudden cardiac death cannot be ruled out <xref ref-type="bibr" rid="pntd.0000383-Collomb1">&#x0005b;3&#x0005d;</xref>. An inflammatory process with accentuation in the conduction system has been observed after treatment in histological studies from HAT patients <xref ref-type="bibr" rid="pntd.0000383-Bertrand1">&#x0005b;6&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Poltera4">&#x0005b;31&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000383-Poltera5">&#x0005b;32&#x0005d;</xref>.</p><p>The appearance and disappearance of repolarization changes at end of treatment were comparable between the DB289 and the pentamidine group. These changes were significantly more frequent than the normal intra-individual fluctuation at baseline and could be due to an unspecific inflammatory reaction to antiparasitic treatment or to a direct cardiotoxic effect of the medication. Histological findings of an accentuation of the inflammatory response have been interpreted as an immune response to dying trypanosomes in treated HAT patients, and could be manifested as repolarization changes <xref ref-type="bibr" rid="pntd.0000383-Poltera6">&#x0005b;33&#x0005d;</xref>. A specific cardiotoxic effect due to a single drug is unlikely to be responsible for the observed repolarization changes, as they were observed with all therapies studied. There was no evidence for other etiologies such as ventricular hypertrophy or coronary heart disease; these were young patients without angina pectoris before and after treatment. Thus, an increase in inflammation is a likely etiology for these transient and dynamic ECG changes that occurred in the setting of anti-parasitic treatment.</p><p>A higher percentage of major ECG alterations after treatment was observed in second stage patients than in first stage patients. A higher grade of inflammation of the heart is likely to occur with progression of the disease and explains the higher rate of treatment-related ECG abnormalities in the eflornithine group. The ECG alterations were well tolerated.</p><p>Limitations of this analysis were that HAT patients and healthy controls were enrolled in different clinical trials. However, the criteria of the interpretation of the ECG recordings were the same in all subjects and were performed and analyzed by the same physician.</p><sec id="s4a"><title>Conclusions</title><p>Cardiac involvement, as demonstrated by ECG alterations, appears early in the evolution of HAT and precedes CNS involvement. As HAT itself was associated with QTc prolongation in more than 10&#x00025; of patients, the additional risk of a drug with potential QTc prolongation properties has to be considered because of the risk of fatal arrhythmias. DB289 and pentamidine treatment were not associated with prolongation of the QTc intervals and they had no obvious cardiotoxic effect. During treatment, ECG changes such as repolarization alterations occurred frequently, were not associated with one specific drug, and were more common in the second stage of the disease.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pntd.0000383.s001"><label>Alternative Language Abstract S1</label><caption><p>Translation of the Abstract into German and French by Johannes Blum</p><p>(0.04 MB DOC)</p></caption><media xlink:href="pntd.0000383.s001.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0000383.s002"><label>Poster S1</label><caption><p>Poster on preliminary results #1</p><p>(0.03 MB DOC)</p></caption><media xlink:href="pntd.0000383.s002.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0000383.s003"><label>Poster S2</label><caption><p>Poster on preliminary results #2</p><p>(2.09 MB PPT)</p></caption><media xlink:href="pntd.0000383.s003.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0000383.s004"><label>Protocol S1</label><caption><p>(0.34 MB PDF)</p></caption><media xlink:href="pntd.0000383.s004.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors wish to thank the study participants, investigators, and coordinators for their participation in this study. The authors further acknowledge the contributions of Dr Sonja Bernhard and Dr Didier Kalemwa from the Swiss Tropical Institute for their efforts in the implementation of the DB289 trials, including the quality assurance and monitoring.</p></ack><ref-list><title>References</title><ref id="pntd.0000383-Blum1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>J</given-names></name><name><surname>Schmid</surname><given-names>C</given-names></name><name><surname>Burri</surname><given-names>C</given-names></name></person-group><year>2006</year><article-title>Clinical aspects of 2541 patients with second stage human African trypanosomiasis.</article-title><source>Acta Trop</source><volume>97</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">16157286</pub-id></citation></ref><ref id="pntd.0000383-Adams1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JH</given-names></name><name><surname>Haller</surname><given-names>L</given-names></name><name><surname>Boa</surname><given-names>FY</given-names></name><name><surname>Doua</surname><given-names>F</given-names></name><name><surname>Dago</surname><given-names>A</given-names></name><name><surname>Konian</surname><given-names>K</given-names></name></person-group><year>1986</year><article-title>Human African trypanosomiasis (T.b. gambiense): a study of 16 fatal cases of sleeping sickness with some observations on acute reactive arsenical encephalopathy.</article-title><source>Neuropathol Appl Neurobiol</source><volume>12</volume><fpage>81</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">3703156</pub-id></citation></ref><ref id="pntd.0000383-Collomb1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collomb</surname><given-names>H</given-names></name><name><surname>Bartoli</surname><given-names>D</given-names></name></person-group><year>1967</year><article-title>&#x0005b;The heart in human African trypanosomiasis caused by Trypanosoma gambiense&#x0005d;.</article-title><source>Bull Soc Pathol Exot Filiales</source><volume>60</volume><fpage>142</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">5632553</pub-id></citation></ref><ref id="pntd.0000383-Blum2"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>JA</given-names></name><name><surname>Burri</surname><given-names>C</given-names></name><name><surname>Hatz</surname><given-names>C</given-names></name><name><surname>Kazumba</surname><given-names>L</given-names></name><name><surname>Mangoni</surname><given-names>P</given-names></name><name><surname>Zellweger</surname><given-names>MJ</given-names></name></person-group><year>2007</year><article-title>Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis).</article-title><source>Trop Med Int Health</source><volume>12</volume><fpage>1422</fpage><lpage>1432</lpage><pub-id pub-id-type="pmid">18076548</pub-id></citation></ref><ref id="pntd.0000383-Fouchet1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fouchet</surname><given-names>M</given-names></name><name><surname>Gateff</surname><given-names>C</given-names></name></person-group><year>1968</year><article-title>&#x0005b;Development of cardiovascular involvement in African trypanosomiasis due to Trypanosoma gambiense&#x0005d;.</article-title><source>Med Trop (Mars)</source><volume>28</volume><fpage>583</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">5706203</pub-id></citation></ref><ref id="pntd.0000383-Bertrand1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertrand</surname><given-names>E</given-names></name><name><surname>Serie</surname><given-names>F</given-names></name><name><surname>Rive</surname><given-names>J</given-names></name><name><surname>Compaore</surname><given-names>P</given-names></name><name><surname>Sentilhes</surname><given-names>L</given-names></name><name><surname>Baudin</surname><given-names>L</given-names></name><name><surname>Renambot</surname><given-names>J</given-names></name><name><surname>Chauvet</surname><given-names>J</given-names></name><name><surname>Ekra</surname><given-names>A</given-names></name><name><surname>Assamoi</surname><given-names>MO</given-names></name></person-group><year>1974</year><article-title>&#x0005b;Current aspects of the cardiac symptoms in African human trypanosomiasis due to Trypanosoma gambiense (apropos of 194 cases)&#x0005d;.</article-title><source>Acta Cardiol</source><volume>29</volume><fpage>363</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">4548789</pub-id></citation></ref><ref id="pntd.0000383-Tsala1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsala</surname><given-names>MP</given-names></name><name><surname>Blackett</surname><given-names>K</given-names></name><name><surname>Mbonifor</surname><given-names>CL</given-names></name><name><surname>Leke</surname><given-names>R</given-names></name><name><surname>Etoundi</surname><given-names>J</given-names></name></person-group><year>1988</year><article-title>&#x0005b;Functional and immunologic involvement in human African trypanosomiasis caused by Trypanosoma gambiense&#x0005d;.</article-title><source>Bull Soc Pathol Exot Filiales</source><volume>81</volume><fpage>490</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">3197247</pub-id></citation></ref><ref id="pntd.0000383-Kuryshev1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuryshev</surname><given-names>YA</given-names></name><name><surname>Ficker</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hawryluk</surname><given-names>P</given-names></name><name><surname>Dennis</surname><given-names>AT</given-names></name><name><surname>Wible</surname><given-names>BA</given-names></name><name><surname>Brown</surname><given-names>AM</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>XL</given-names></name><name><surname>Sawamura</surname><given-names>K</given-names></name><name><surname>Reynolds</surname><given-names>W</given-names></name><name><surname>Rampe</surname><given-names>D</given-names></name></person-group><year>2005</year><article-title>Pentamidine-induced long QT syndrome and block of hERG trafficking.</article-title><source>J Pharmacol Exp Ther</source><volume>312</volume><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">15340016</pub-id></citation></ref><ref id="pntd.0000383-Jones1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>IG</given-names></name><name><surname>Lowenthal</surname><given-names>MN</given-names></name><name><surname>Buyst</surname><given-names>H</given-names></name></person-group><year>1975</year><article-title>Electrocardiographic changes in African trypanosomiasis caused by Trypanosoma brucei rhodesiense.</article-title><source>Trans R Soc Trop Med Hyg</source><volume>69</volume><fpage>388</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">1216299</pub-id></citation></ref><ref id="pntd.0000383-DeRaadt1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Raadt</surname><given-names>P</given-names></name><name><surname>Koten</surname><given-names>JW</given-names></name></person-group><year>1968</year><article-title>Myocarditis in Rhodesiense trypanosomiasis.</article-title><source>East Afr Med J</source><volume>45</volume><fpage>128</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">5658188</pub-id></citation></ref><ref id="pntd.0000383-Koten1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koten</surname><given-names>JW</given-names></name><name><surname>De Raadt</surname><given-names>P</given-names></name></person-group><year>1969</year><article-title>Myocarditis in Trypanosoma rhodesiense infections.</article-title><source>Trans R Soc Trop Med Hyg</source><volume>63</volume><fpage>485</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">4980627</pub-id></citation></ref><ref id="pntd.0000383-Bertrand2"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertrand</surname><given-names>E</given-names></name><name><surname>Sentilhes</surname><given-names>L</given-names></name><name><surname>Ducasse</surname><given-names>B</given-names></name><name><surname>Vacher</surname><given-names>P</given-names></name><name><surname>Baudin</surname><given-names>L</given-names></name></person-group><year>1965</year><article-title>&#x0005b;Heart involvement in African trypanosomiasis due to Trypanosoma gambiense. Apropos of especially the ECG verifications in 60 patients&#x0005d;.</article-title><source>Med Trop (Mars)</source><volume>25</volume><fpage>603</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">5860644</pub-id></citation></ref><ref id="pntd.0000383-Bertrand3"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertrand</surname><given-names>E</given-names></name><name><surname>Baudin</surname><given-names>L</given-names></name><name><surname>Vacher</surname><given-names>P</given-names></name><name><surname>Sentilhes</surname><given-names>L</given-names></name><name><surname>Ducasse</surname><given-names>B</given-names></name><name><surname>Veyret</surname><given-names>V</given-names></name></person-group><year>1967</year><article-title>&#x0005b;Impairment of the heart in 100 cases of African trypanosomiasis due to Trypanosoma gambiense&#x0005d;.</article-title><source>Bull Soc Pathol Exot Filiales</source><volume>60</volume><fpage>360</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">5632305</pub-id></citation></ref><ref id="pntd.0000383-Bertrand4"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertrand</surname><given-names>E</given-names></name><name><surname>Sentilhes</surname><given-names>L</given-names></name><name><surname>Ducasse</surname><given-names>M</given-names></name><name><surname>Vacher</surname><given-names>P</given-names></name><name><surname>Baudin</surname><given-names>L</given-names></name><name><surname>Serie</surname><given-names>F</given-names></name></person-group><year>1966</year><article-title>&#x0005b;Systematic study of the electrocardiogram in African trypanosomiasis due to Trypanosoma gambiense. (Apropos of 60 patients)&#x0005d;.</article-title><source>Arch Mal Coeur Vaiss</source><volume>59</volume><fpage>1220</fpage><lpage>1234</lpage><pub-id pub-id-type="pmid">4961364</pub-id></citation></ref><ref id="pntd.0000383-Burri1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burri</surname><given-names>C</given-names></name><name><surname>Nkunku</surname><given-names>S</given-names></name><name><surname>Merolle</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>T</given-names></name><name><surname>Blum</surname><given-names>J</given-names></name><name><surname>Brun</surname><given-names>R</given-names></name></person-group><year>2000</year><article-title>Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial.</article-title><source>Lancet</source><volume>355</volume><fpage>1419</fpage><lpage>1425</lpage><pub-id pub-id-type="pmid">10791526</pub-id></citation></ref><ref id="pntd.0000383-Blum3"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>J</given-names></name><name><surname>Burri</surname><given-names>C</given-names></name></person-group><year>2002</year><article-title>Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug.</article-title><source>Swiss Med Wkly</source><volume>132</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">11971197</pub-id></citation></ref><ref id="pntd.0000383-Chappuis1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chappuis</surname><given-names>F</given-names></name><name><surname>Udayraj</surname><given-names>N</given-names></name><name><surname>Stietenroth</surname><given-names>K</given-names></name><name><surname>Meussen</surname><given-names>A</given-names></name><name><surname>Bovier</surname><given-names>PA</given-names></name></person-group><year>2005</year><article-title>Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.</article-title><source>Clin Infect Dis</source><volume>41</volume><fpage>748</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">16080099</pub-id></citation></ref><ref id="pntd.0000383-AlKhatib1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al Khatib</surname><given-names>SM</given-names></name><name><surname>LaPointe</surname><given-names>NM</given-names></name><name><surname>Kramer</surname><given-names>JM</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name></person-group><year>2003</year><article-title>What clinicians should know about the QT interval.</article-title><source>JAMA</source><volume>289</volume><fpage>2120</fpage><lpage>2127</lpage><pub-id pub-id-type="pmid">12709470</pub-id></citation></ref><ref id="pntd.0000383-Moss1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>AJ</given-names></name></person-group><year>1993</year><article-title>Measurement of the QT interval and the risk associated with QTc interval prolongation: a review.</article-title><source>Am J Cardiol</source><volume>72</volume><fpage>23B</fpage><lpage>25B</lpage></citation></ref><ref id="pntd.0000383-Wang1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Asinger</surname><given-names>RW</given-names></name><name><surname>Marriott</surname><given-names>HJ</given-names></name></person-group><year>2003</year><article-title>ST-segment elevation in conditions other than acute myocardial infarction.</article-title><source>N Engl J Med</source><volume>349</volume><fpage>2128</fpage><lpage>2135</lpage><pub-id pub-id-type="pmid">14645641</pub-id></citation></ref><ref id="pntd.0000383-White1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name></person-group><year>1988</year><article-title>Drug treatment and prevention of malaria.</article-title><source>Eur J Clin Pharmacol</source><volume>34</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">3282892</pub-id></citation></ref><ref id="pntd.0000383-Luzzi1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luzzi</surname><given-names>GA</given-names></name><name><surname>Peto</surname><given-names>TE</given-names></name></person-group><year>1993</year><article-title>Adverse effects of antimalarials. An update.</article-title><source>Drug Saf</source><volume>8</volume><fpage>295</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">8481216</pub-id></citation></ref><ref id="pntd.0000383-Luzzi2"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luzzi</surname><given-names>GA</given-names></name><name><surname>Peto</surname><given-names>TE</given-names></name></person-group><year>1993</year><article-title>Adverse effects of antimalarials. An update.</article-title><source>Drug Saf</source><volume>8</volume><fpage>295</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">8481216</pub-id></citation></ref><ref id="pntd.0000383-Bertrand5"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertrand</surname><given-names>E</given-names></name><name><surname>Serie</surname><given-names>F</given-names></name><name><surname>Kone</surname><given-names>I</given-names></name><name><surname>Rive</surname><given-names>J</given-names></name><name><surname>Campaore</surname><given-names>P</given-names></name><name><surname>Sentilhes</surname><given-names>L</given-names></name><name><surname>Philippe</surname><given-names>J</given-names></name></person-group><year>1973</year><article-title>Symptomatologie g&#x000e9;n&#x000e9;rale de la trypanosomiase humaine africaine au moment du d&#x000e9;pistage.</article-title><source>M&#x000e9;decine d'Afrique Noire</source><volume>20</volume><fpage>303</fpage><lpage>314</lpage></citation></ref><ref id="pntd.0000383-Poltera1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poltera</surname><given-names>AA</given-names></name><name><surname>Sayer</surname><given-names>PD</given-names></name><name><surname>Rudin</surname><given-names>W</given-names></name><name><surname>Bovell</surname><given-names>D</given-names></name></person-group><year>1985</year><article-title>Trypanosomal cardiac valvulitis in vervet monkeys.</article-title><source>Trop Med Parasitol</source><volume>36</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">4023556</pub-id></citation></ref><ref id="pntd.0000383-Poltera2"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poltera</surname><given-names>AA</given-names></name><name><surname>Sayer</surname><given-names>PD</given-names></name></person-group><year>1983</year><article-title>Cardiac lymph drainage in experimental African trypanosomiasis in vervet monkeys.</article-title><source>Bull Soc Pathol Exot Filiales</source><volume>76</volume><fpage>614</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">6673854</pub-id></citation></ref><ref id="pntd.0000383-Poltera3"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poltera</surname><given-names>AA</given-names></name></person-group><year>1980</year><article-title>Immunopathological and chemotherapeutic studies in experimental trypanosomiasis with special reference to the heart and brain.</article-title><source>Trans R Soc Trop Med Hyg</source><volume>74</volume><fpage>706</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">7210124</pub-id></citation></ref><ref id="pntd.0000383-CostelloBoerrigter1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costello-Boerrigter</surname><given-names>LC</given-names></name><name><surname>Boerrigter</surname><given-names>G</given-names></name><name><surname>Redfield</surname><given-names>MM</given-names></name><name><surname>Rodeheffer</surname><given-names>RJ</given-names></name><name><surname>Urban</surname><given-names>LH</given-names></name><name><surname>Mahoney</surname><given-names>DW</given-names></name><name><surname>Jacobsen</surname><given-names>SJ</given-names></name><name><surname>Heublein</surname><given-names>DM</given-names></name><name><surname>Burnett</surname><given-names>JC</given-names><suffix>Jr</suffix></name></person-group><year>2006</year><article-title>Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.</article-title><source>J Am Coll Cardiol</source><volume>47</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">16412859</pub-id></citation></ref><ref id="pntd.0000383-Damian1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Damian</surname><given-names>MS</given-names></name><name><surname>Dorndorf</surname><given-names>W</given-names></name><name><surname>Burkardt</surname><given-names>H</given-names></name><name><surname>Singer</surname><given-names>I</given-names></name><name><surname>Leinweber</surname><given-names>B</given-names></name><name><surname>Schachenmayr</surname><given-names>W</given-names></name></person-group><year>1994</year><article-title>&#x0005b;Polyneuritis and myositis in Trypanosoma gambiense infection&#x0005d;.</article-title><source>Dtsch Med Wochenschr</source><volume>119</volume><fpage>1690</fpage><lpage>1693</lpage><pub-id pub-id-type="pmid">7988374</pub-id></citation></ref><ref id="pntd.0000383-Croft1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Croft</surname><given-names>AM</given-names></name><name><surname>Jackson</surname><given-names>CJ</given-names></name><name><surname>Friend</surname><given-names>HM</given-names></name><name><surname>Minton</surname><given-names>EJ</given-names></name></person-group><year>2006</year><article-title>African trypanosomiasis in a British soldier.</article-title><source>J R Army Med Corps</source><volume>152</volume><fpage>156</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">17295013</pub-id></citation></ref><ref id="pntd.0000383-Poltera4"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poltera</surname><given-names>AA</given-names></name><name><surname>Cox</surname><given-names>JN</given-names></name><name><surname>Owor</surname><given-names>R</given-names></name></person-group><year>1976</year><article-title>Pancarditis affecting the conducting system and all valves in human African trypanosomiasis.</article-title><source>Br Heart J</source><volume>38</volume><fpage>827</fpage><lpage>837</lpage><pub-id pub-id-type="pmid">973907</pub-id></citation></ref><ref id="pntd.0000383-Poltera5"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poltera</surname><given-names>AA</given-names></name><name><surname>Hochmann</surname><given-names>A</given-names></name><name><surname>Lambert</surname><given-names>PH</given-names></name></person-group><year>1980</year><article-title>A model for cardiopathy induced by Trypanosoma brucei brucei in mice. A histologic and immunopathologic study.</article-title><source>Am J Pathol</source><volume>99</volume><fpage>325</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">6990771</pub-id></citation></ref><ref id="pntd.0000383-Poltera6"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poltera</surname><given-names>AA</given-names></name><name><surname>Hochmann</surname><given-names>A</given-names></name><name><surname>Lambert</surname><given-names>PH</given-names></name></person-group><year>1981</year><article-title>Trypanosoma brucei brucei: the response to Melarsoprol in mice with cerebral trypanosomiasis. An immunopathological study.</article-title><source>Clin Exp Immunol</source><volume>46</volume><fpage>363</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">7039886</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p>The Melinda and Bill Gates Foundation funded the clinical trials of DB289 (pafuramidine maleate) phases IIa, IIb, IIb2, III. The study on late stage patients compared to healthy controls was funded by Schweizerische Herzstiftung, the Margarethe and Walter Lichtestein Stiftung, the Freiwillige Akademische Gesellschaft. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>